New monoclonal antibodies in targeted therapy of allergic diseases

Monoclonal antibodies have significantly expanded the therapeutic options for severe allergic diseases by targeting key mechanisms in their pathogenesis. This review briefly presents data on the efficacy and safety of monoclonal antibodies that are not registered in the Russian Federation but have successfully completed late-stage clinical trials or have been approved by the U. S. FDA for the treatment of asthma, atopic eczema, allergic rhinitis, eosinophilic esophagitis, food allergy and chronic spontaneous urticaria. Further research is needed to evaluate their long-term safety, along with efforts to address registration challenges and to make these drugs more accessible for routine medical practice in the Russian Federation.